Gyre Therapeutics
GYRE
48 hedge funds and large institutions have $25.1M invested in Gyre Therapeutics in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 8 reducing their positions, and 8 closing their positions.
213% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 8
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
24% more capital invested
Capital invested by funds: $20.1M → $25.1M (+$4.92M)
4% more funds holding
Funds holding: 46 → 48 (+2)
0.6% more ownership
Funds ownership: 3.04% → 3.64% (+0.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.58M |
| 2 |
SS
SBI Securities
Tokyo,
Japan
|
+$948K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$780K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$464K |
| 5 |
State Street
Boston,
Massachusetts
|
+$427K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$137K |
| 2 |
Goldman Sachs
New York
|
-$125K |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$109K |
| 4 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
-$105K |
| 5 |
CF
Corebridge Financial
Houston,
Texas
|
-$26.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Lazard Asset Management
New York
| – | -$6K | -833 | Closed |
|
52
Group One Trading
Chicago,
Illinois
| – | -$3.74K | -485 | Closed |
|
|
EWA
53
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$170 | -22 | Closed |
|
54
US Bancorp
Minneapolis,
Minnesota
| – | -$131 | -17 | Closed |
|
|
TWD
55
True Wealth Design
Akron,
Ohio
| – | -$47 | -6 | Closed |
|
|
C
56
Covestor
London,
United Kingdom
| – | -$9 | -1 | -14% |
|
GYRE Hedge Fund Activity: Q2 2025 in Review
48 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2025, worth a combined $25.1M — up 24% from $20.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GYRE positions and 8 closed out — a net gain of 2 holders — while 25 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $2.58M. The largest seller was UBS Group, cutting an estimated $137K.
- 48 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2025, up from 46 in Q1 2025.
- Funds reported $25.1M of Gyre Therapeutics stock for Q2 2025, up 24% quarter-over-quarter.
- 10 funds opened new Gyre Therapeutics positions in Q2 2025 and 8 closed out, a net change of +2 holders.
- The largest Gyre Therapeutics buyer in Q2 2025 was BlackRock, an estimated $2.58M added.
- The largest Gyre Therapeutics seller in Q2 2025 was UBS Group, an estimated $137K sold.
Based on aggregated 13F filings for Q2 2025.